Sugi Predict

Sugi Predict / Targets / PIK3C2A

PIK3C2A

Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha · O00443 · PIK3C2A on Sugi Atlas →

9,300 patent compounds predicted against PIK3C2A, 6,897 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Dactolisib Dactolisib (SCHEMBL143623) 1.00 2/20
Pi-103 Pi-103 (SCHEMBL258242) 1.00 2/20
SCHEMBL368176 SCHEMBL368176 0.77 2/20
SCHEMBL368177 SCHEMBL368177 0.77 2/20
SCHEMBL191468 SCHEMBL191468 0.68 2/20
SCHEMBL191469 SCHEMBL191469 0.68 2/20
SCHEMBL903049 SCHEMBL903049 0.61 2/20
SCHEMBL926025 SCHEMBL926025 0.59 2/20
SCHEMBL925745 SCHEMBL925745 0.58 2/20
SCHEMBL925110 SCHEMBL925110 0.57 2/20
SCHEMBL926465 SCHEMBL926465 0.57 2/20
SCHEMBL368220 SCHEMBL368220 0.56 2/20
SCHEMBL369057 SCHEMBL369057 0.56 2/20
SCHEMBL369058 SCHEMBL369058 0.56 2/20
SCHEMBL924804 SCHEMBL924804 0.56 2/20
SCHEMBL367631 SCHEMBL367631 0.56 2/20
SCHEMBL367632 SCHEMBL367632 0.56 2/20
SCHEMBL369464 SCHEMBL369464 0.56 2/20
SCHEMBL924751 SCHEMBL924751 0.55 2/20
SCHEMBL925032 SCHEMBL925032 0.55 2/20

Clinical trials — most relevant to PIK3C2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care PHASE3RECRUITING
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome PHASE2WITHDRAWN
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer nanWITHDRAWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies nanNOT_YET_RECRUITING
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Exploring the Link Between Cancer Genetics and PPSP nanUNKNOWN
Study of Proteus Syndrome and Related Congenital Disorders nanRECRUITING
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PIK3C2A binder may also engage these)

ProteinNameSimilarity
Q5RAY1 — 1.000 Q5RAY1 →
Q61194 — 1.000 Q61194 →
Q5HZN1 — 0.999 Q5HZN1 →
A6QP06 — 0.999 A6QP06 →
Q6DDJ5 — 0.998 Q6DDJ5 →
A7YDW0 — 0.998 A7YDW0 →
Q6NU22 — 0.997 Q6NU22 →
Q17QK1 — 0.997 Q17QK1 →
Q9VQ36 — 0.997 Q9VQ36 →
G5EDY0 — 0.997 G5EDY0 →
Q9DDT2 — 0.997 Q9DDT2 →
Q7Z3E5 — 0.997 Q7Z3E5 →
Q99PI5 — 0.997 Q99PI5 →
Q0VF22 — 0.996 Q0VF22 →
Q8BMD7 — 0.996 Q8BMD7 →
Q2PFD7 — 0.996 Q2PFD7 →
Q95JJ5 — 0.996 Q95JJ5 →
Q92539 — 0.996 Q92539 →
Q92540 — 0.996 Q92540 →
Q9FY74 — 0.995 Q9FY74 →
Q5TH69 — 0.995 Q5TH69 →
Q8WML3 — 0.995 Q8WML3 →
A5HEI1 — 0.995 A5HEI1 →
F4K4J0 — 0.995 F4K4J0 →
Q6GM71 — 0.995 Q6GM71 →
Q5ICL9 — 0.995 Q5ICL9 →
B5E0H4 — 0.995 B5E0H4 →
Q8K3E5 — 0.995 Q8K3E5 →
Q6DJR2 — 0.995 Q6DJR2 →
Q5TKR9 — 0.995 Q5TKR9 →